AP2064A - Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors - Google Patents

Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors

Info

Publication number: AP2064A
Authority: AP; ARIPO
Prior art keywords: pyrazolo; preparation; kinase inhibitors; quinazoline derivatives; quinazoline
Prior art date: 2003-05-22

Application number

AP2005003452A

Other languages

English (en)

Other versions

AP2005003452A0 (en

Inventor

Gabriella Traquandi

Maria Gabriella Brasca

Roberto D'alessio

Original Assignee

Nerviano Medical Sciences Srl

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-05-22

Filing date

2004-04-27

Publication date

2009-10-30

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33476970&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AP2064(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2004-04-27 Application filed by Nerviano Medical Sciences Srl filed Critical Nerviano Medical Sciences Srl

2005-12-31 Publication of AP2005003452A0 publication Critical patent/AP2005003452A0/xx

2009-10-30 Application granted granted Critical

2009-10-30 Publication of AP2064A publication Critical patent/AP2064A/xx

Links

GNOYRJIXSUNXIH-UHFFFAOYSA-N N1=CNC2=C3C=NN=C3C=CC2=C1 Chemical class N1=CNC2=C3C=NN=C3C=CC2=C1 GNOYRJIXSUNXIH-UHFFFAOYSA-N 0.000 title 1
229940043355 kinase inhibitor Drugs 0.000 title 1
239000003757 phosphotransferase inhibitor Substances 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Epidemiology (AREA)
Oncology (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Virology (AREA)
Neurosurgery (AREA)
Urology & Nephrology (AREA)
Dermatology (AREA)
Rheumatology (AREA)
Communicable Diseases (AREA)
Cardiology (AREA)
Molecular Biology (AREA)
Tropical Medicine & Parasitology (AREA)
Heart & Thoracic Surgery (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Transplantation (AREA)
Hospice & Palliative Care (AREA)
Pulmonology (AREA)
Hematology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
AIDS & HIV (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

AP2005003452A 2003-05-22 2004-04-27 Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors AP2064A (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US47266103P	2003-05-22	2003-05-22
PCT/EP2004/050612 WO2004104007A1 (en)	2003-05-22	2004-04-27	Pyrazolo-quinazoline derivatives,process for their preparation and their use as kinase inhibitors

Publications (2)

Publication Number	Publication Date
AP2005003452A0 AP2005003452A0 (en)	2005-12-31
AP2064A true AP2064A (en)	2009-10-30

Family

ID=33476970

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AP2005003452A AP2064A (en)	2003-05-22	2004-04-27	Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors

Country Status (36)

Country	Link
US (9)	US7482354B2 (es)
EP (1)	EP1636236B1 (es)
JP (1)	JP5043432B2 (es)
KR (1)	KR101084871B1 (es)
CN (2)	CN102079746A (es)
AP (1)	AP2064A (es)
AR (2)	AR044543A1 (es)
AU (1)	AU2004240772B2 (es)
BR (2)	BR122019010200B8 (es)
CA (1)	CA2526578C (es)
CO (1)	CO5721006A2 (es)
CR (1)	CR8102A (es)
CY (1)	CY1114708T1 (es)
DK (1)	DK1636236T3 (es)
EA (1)	EA010904B1 (es)
EC (1)	ECSP056194A (es)
ES (1)	ES2436524T3 (es)
GE (1)	GEP20094664B (es)
HR (1)	HRP20050967B8 (es)
IL (1)	IL172046A (es)
IS (1)	IS2939B (es)
ME (1)	ME00142B (es)
MX (1)	MXPA05012573A (es)
MY (1)	MY142019A (es)
NO (1)	NO334992B1 (es)
NZ (1)	NZ543661A (es)
OA (1)	OA13170A (es)
PL (1)	PL1636236T3 (es)
PT (1)	PT1636236E (es)
RS (2)	RS20050944A (es)
SI (1)	SI1636236T1 (es)
TN (1)	TNSN05298A1 (es)
TW (1)	TWI349672B (es)
UA (1)	UA80763C2 (es)
WO (1)	WO2004104007A1 (es)
ZA (1)	ZA200509486B (es)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2436524T3 (es) *	2003-05-22	2014-01-02	Nerviano Medical Sciences S.R.L.	Derivados de pirazolo-quinazolina, procedimiento para su preparación y su uso como inhibidores de cinasas
CN1897950A (zh) *	2003-10-14	2007-01-17	惠氏公司	稠合芳基和杂芳基衍生物及其使用方法
US7572914B2 (en)	2003-12-19	2009-08-11	Takeda Pharmaceutical Company Limited	Kinase inhibitors
US7772232B2 (en) *	2004-04-15	2010-08-10	Bristol-Myers Squibb Company	Quinazolinyl compounds as inhibitors of potassium channel function
ITMI20041033A1 (it) *	2004-05-24	2004-08-24	Neuroscienze S C A R L	Composti farmaceutici
WO2006023931A2 (en)	2004-08-18	2006-03-02	Takeda San Diego, Inc.	Kinase inhibitors
EP1812439B2 (en)	2004-10-15	2017-12-06	Takeda Pharmaceutical Company Limited	Kinase inhibitors
US8119655B2 (en)	2005-10-07	2012-02-21	Takeda Pharmaceutical Company Limited	Kinase inhibitors
ES2390237T3 (es)	2006-02-10	2012-11-07	Nerviano Medical Sciences S.R.L.	Combinaciones que comprenden un inhibidor de cdk y un anticuerpo anti-factor de crecimiento o un agente antimitótico
JP2009536180A (ja) *	2006-05-09	2009-10-08	ノバルティスアクチエンゲゼルシャフト	鉄キレート剤と抗新生物剤を含む組合せ剤およびそれらの使用
US20080015193A1 (en) *	2006-06-20	2008-01-17	Mendoza Jose S	Certain azoles exhibiting ATP-utilizing enzyme inhibitory activity, compositions, and uses thereof
US7517882B2 (en) *	2006-09-18	2009-04-14	Polaris Group	Protein kinase inhibitors
JP2010505962A (ja)	2006-10-09	2010-02-25	武田薬品工業株式会社	キナーゼ阻害剤
UA102219C2 (ru) *	2006-12-21	2013-06-25	НЕРВИАНО МЕДИКАЛ САЙЕНСИЗ С.р.л.	Замещенные пиразолохиназолиновые производные, способ их получения и их применения как ингибиторов киназы
PL2125822T3 (pl) *	2006-12-21	2015-04-30	Nerviano Medical Sciences Srl	Podstawione pochodne pirazolochinazoliny, sposób ich wytwarzania oraz ich zastosowanie jako inhibitory kinaz
EP2213673B1 (en)	2007-10-23	2013-06-05	Msd K.K.	Pyridone-substituted-dihydropyrazolopyrimidinone derivative
AU2008343932B2 (en)	2007-12-19	2013-08-15	Amgen Inc.	Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors
ATE531372T1 (de) *	2008-04-07	2011-11-15	Amgen Inc	Gem-disubstituierte und spirocyclische aminopyridine/pyrimidine als zellcyclus- inhibitoren
TWI426074B (zh) *	2008-04-30	2014-02-11	Nerviano Medical Sciences Srl	５－（２－胺基－嘧啶－４－基）－２－芳基－１ｈ－吡咯－３－羧醯胺之製造方法
BRPI0914649B1 (pt) *	2008-06-26	2021-07-06	Les Laboratoires Servier	Pirazolo-quinazolinas
ES2622559T3 (es) *	2008-07-29	2017-07-06	Nerviano Medical Sciences S.R.L.	Combinación terapéutica que comprende un inhibidor de cdk y un agente antineoplásico
CN102105151B (zh) *	2008-07-29	2013-12-18	内尔维阿诺医学科学有限公司	Cdk抑制剂在治疗神经胶质瘤中的应用
JP5579724B2 (ja) *	2008-10-17	2014-08-27	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	ホスファチジルイノシトール−３−キナーゼ（ｐｉ−３キナーゼ）阻害剤としてのテトラ−アザ−複素環
US8912194B2 (en) *	2008-11-24	2014-12-16	Nerviano Medical Sciences S.R.L.	CDK inhibitor for the treatment of mesothelioma
IT1395724B1 (it) *	2009-02-25	2012-10-19	Neuroscienze Pharmaness S C A R L	Composti farmaceutici
WO2010106028A1 (en) *	2009-03-20	2010-09-23	Nerviano Medical Sciences S.R.L.	Use of a kinase inhibitor for the treatment of thymoma
EP2421872B1 (en) *	2009-04-22	2015-06-10	Boehringer Ingelheim International GmbH	Thia-triaza-as-indacenes as pi3-kinases inhibitors for the treatment of cancer
WO2010125004A1 (en)	2009-04-29	2010-11-04	Nerviano Medical Sciences S.R.L.	Cdk inhibitor salts
AR076784A1 (es)	2009-05-26	2011-07-06	Nerviano Medical Sciences Srl	Combinacion terapeutica que comprende un inhibidor de plk1 y un agente antineoplasico
ES2553114T3 (es) *	2009-07-29	2015-12-04	Nerviano Medical Sciences S.R.L.	Sales de inhibidor de plk
KR20120117905A (ko) *	2010-01-28	2012-10-24	프레지던트 앤드 펠로우즈 오브 하바드 칼리지	프로테아좀 활성을 향상시키는 조성물 및 방법
US8735386B2 (en)	2010-07-23	2014-05-27	Boehringer Ingelheim International Gmbh	Aminopyrazoloquinazolines
US9333205B2 (en)	2010-07-30	2016-05-10	Nerviano Medical Sciences S.R.L.	Isoxazolo-quinazolines as modulators of protein kinase activity
WO2012038521A1 (en)	2010-09-23	2012-03-29	Syngenta Participations Ag	Novel microbiocides
KR102186969B1 (ko) *	2010-10-25	2020-12-04	쥐원 쎄라퓨틱스, 인크.	Cdk 억제제
BR112013008527A2 (pt) *	2010-12-17	2016-07-12	Nerviano Medical Sciences Srl	derivados de pirazolo-quinazolina substituídos como inibidores de cinase
US8975267B2 (en) *	2011-01-26	2015-03-10	Nerviano Medical Sciences S.R.L.	Tricyclic pyrrolo derivatives, process for their preparation and their use as kinase inhibitors
EP2668188B1 (en) *	2011-01-26	2016-05-18	Nerviano Medical Sciences S.r.l.	Tricyclic derivatives, process for their preparation and their use as kinase inhibitors
WO2012117021A2 (en)	2011-03-03	2012-09-07	Syngenta Participations Ag	Novel microbiocidal oxime ethers
KR101606250B1 (ko)	2011-03-23	2016-03-24	암젠 인크	Cdk 4/6 및 flt3의 융합된 트리사이클릭 이중 저해제
TR201906779T4 (tr)	2011-05-12	2019-05-21	Proteostasis Therapeutics Inc	Proteostaz regülatörleri.
WO2013092460A1 (en)	2011-12-20	2013-06-27	Syngenta Participations Ag	Cyclic bisoxime microbicides
EP2807166B1 (en) *	2012-01-23	2016-04-06	Boehringer Ingelheim International GmbH	5,8-dihydro-6h-pyrazolo[3,4-h]quinazolines as igf-1r/ir inhibitors
EP2641901A1 (en)	2012-03-22	2013-09-25	Syngenta Participations AG.	Novel microbiocides
EP2917214B1 (en)	2012-11-07	2019-08-28	Nerviano Medical Sciences S.r.l.	Substituted pyrimidinyl and pyridinyl-pyrrolopyridinones, process for their preparation and their use as kinase inhibitors
WO2014116228A1 (en)	2013-01-25	2014-07-31	President And Fellows Of Harvard College	Usp14 inhibitors for treating or preventing viral infections
CA2906157C (en)	2013-03-15	2022-05-17	G1 Therapeutics, Inc.	Highly active anti-neoplastic and anti-proliferative agents
JP6430483B2 (ja)	2013-03-15	2018-11-28	ジー１、セラピューティクス、インコーポレイテッドＧ１Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ．	化学療法の間の正常細胞の一時的な保護
WO2015073528A1 (en)	2013-11-12	2015-05-21	Proteostasis Therapeutics, Inc.	Proteasome activity enhancing compounds
CA2944610C (en)	2014-04-07	2024-01-09	Netherlands Translational Research Center B.V.	(5,6-dihydro)pyrimido[4,5-e]indolizines
WO2015161283A1 (en)	2014-04-17	2015-10-22	G1 Therapeutics, Inc.	Tricyclic lactams for use in hspc-sparing treatments for rb-positive abnormal cellular proliferation
EP3148532B1 (en)	2014-05-28	2021-03-03	Piramal Enterprises Limited	Pharmaceutical combination comprising a cdk inhibitor and a thioredoxin reductase inhibitor for the treatment of cancer
EP3191098A4 (en)	2014-09-12	2018-04-25	G1 Therapeutics, Inc.	Combinations and dosing regimes to treat rb-positive tumors
WO2016040848A1 (en)	2014-09-12	2016-03-17	G1 Therapeutics, Inc.	Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors
EP3799873A1 (en)	2015-07-17	2021-04-07	Institut Pasteur	5-hydroxytryptamine 1b receptor-stimulating agent for use as a promoter of satellite cells self-renewal and/or differentiation
BR112019000706A8 (pt)	2016-07-15	2022-12-06	Pasteur Institut	Agente de estímulo do receptor 1b de 5-hidroxitriptamina para reparo de pele e/ou cabelo
CN108699067B (zh) *	2016-11-11	2021-06-15	上海海雁医药科技有限公司	吡啶胺取代的杂三环化合物、其制法与医药上的用途
WO2019011715A1 (en)	2017-07-11	2019-01-17	Nerviano Medical Sciences S.R.L.	PYRAZOLO-QUINAZOLINE DERIVATIVES AS INHIBITORS OF CHOLINE KINASE
CN107383019B (zh) *	2017-07-28	2019-10-15	江苏艾凡生物医药有限公司	吡唑并[4,3-h]喹唑啉类化合物及其用途
KR102464677B1 (ko) *	2017-08-11	2022-11-10	셍커 파마슈티컬스 (지앙수) 엘티디.	단백질 인산화효소 억제제로 작용하는 1h-피라졸로[4,3-h]퀴나졸린 화합물
BR112021022538A2 (pt) *	2019-06-06	2021-12-28	Arcus Biosciences Inc	Processos para preparar compostos de aminopirimidina
WO2021043190A1 (zh) *	2019-09-05	2021-03-11	成都赛诺希亚生物科技有限公司	异噁唑并[5,4-h]喹唑啉类化合物作为蛋白激酶抑制剂
WO2021084541A1 (en) *	2019-10-31	2021-05-06	Sol-Gel Technologies Ltd.	Treatment of hair loss disorders with a topical egfr inhibitor
US10988479B1 (en)	2020-06-15	2021-04-27	G1 Therapeutics, Inc.	Morphic forms of trilaciclib and methods of manufacture thereof
CN116547280A (zh) *	2020-10-08	2023-08-04	雷多纳治疗公司	用于治疗癌症的苯并[h]喹唑啉-4-胺和噻吩并[3,2-h]喹唑啉-4-胺衍生物
CA3195150A1 (en)	2020-10-08	2022-04-14	Sven Weiler	Benzo[h]quinazolin-4-amine and thieno[3,2-h]quinazolin-4-amine derivatives for the treatment of cancer
US20230416271A1 (en) *	2020-11-26	2023-12-28	Chengdu Cynogen Bio-Pharmaceutical Technology Co., Ltd.	Heteroarylquinazoline compounds as protein kinase inhibitors
CN114685520B (zh) *	2020-12-25	2024-08-30	武汉誉祥医药科技有限公司	三并环化合物及其药物组合物和应用
WO2022143576A1 (zh) *	2020-12-31	2022-07-07	恒元生物医药科技(苏州)有限公司	一种吡唑并喹唑啉类化合物、其制备方法及应用
US12577253B2 (en)	2021-02-08	2026-03-17	Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd.	5,6-dihydrothieno[3,4-h]quinazoline compound
IL309569A (en) *	2021-06-22	2024-02-01	Taxis Pharmaceuticals Inc	Therapeutic compounds
CN113527310B (zh) *	2021-07-30	2022-09-23	上海市肺科医院	用于减轻自身免疫性疾病患者不良炎性反应的小分子化合物及其应用
JP2024546115A (ja) *	2021-12-10	2024-12-17	シャンドンルイファーマシューティカルカンパニーリミテッド	プロテインキナーゼ阻害剤及びその製造方法と応用
WO2024153110A1 (zh) *	2023-01-17	2024-07-25	北京哲源科技有限责任公司	吡唑并喹唑啉类化合物的立体异构体和氘代衍生物及应用
EP4725947A1 (en) *	2023-06-08	2026-04-15	Shandong Luye Pharmaceutical Co., Ltd.	Salt form and crystal form of plk1 kinase inhibitor, and preparation method therefor and use thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2119975A (en) *	1936-08-26	1938-06-07	Beatrice S Nazel	Fluid pressure hammer

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP3907220B2 (ja) *	1994-06-30	2007-04-18	エーザイ・アール・アンド・ディー・マネジメント株式会社	複素環含有化合物
CA2223081C (en)	1995-06-07	2001-03-06	Pfizer Inc.	Heterocyclic ring-fused pyrimidine derivatives
AU5330698A (en)	1996-12-23	1998-07-17	Celltech Therapeutics Limited	Fused polycyclic 2-aminopyrimidine derivatives, their preparation and their use as protein tyrosine kinase inhibitors
GB9713087D0 (en)	1997-06-20	1997-08-27	Celltech Therapeutics Ltd	Chemical compounds
GB9911053D0 (en)	1999-05-12	1999-07-14	Pharmacia & Upjohn Spa	4,5,6,7-tetrahydroindazole derivatives process for their preparation and their use as antitumour agents
MXPA02001498A (es)	1999-08-12	2003-07-21	Pharmacia & Italia S P A	Derivados de 3(5)-amino-pirazol, procedimiento para la preparacion de los mismos y usos como agentes antitumorales.
US6387900B1 (en)	1999-08-12	2002-05-14	Pharmacia & Upjohn S.P.A.	3(5)-ureido-pyrazole derivatives process for their preparation and their use as antitumor agents
CA2416527C (en)	2000-08-10	2009-12-22	Pharmacia Italia S.P.A.	Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
EP1309596B1 (en) *	2000-08-11	2008-02-06	Boehringer Ingelheim Pharmaceuticals Inc.	Heterocyclic compounds useful as inhibitors of tyrosine kinases
AU2002215053A1 (en)	2000-11-27	2002-06-24	Pharmacia Italia S.P.A.	Phenylacetamido- pyrazole derivatives and their use as antitumor agents
US20040116497A1 (en)	2001-01-26	2004-06-17	Gabriella Traquandi	Chromane derivatives, process for their preparation and their use as antitumor agents
US20030100594A1 (en) *	2001-08-10	2003-05-29	Pharmacia Corporation	Carbonic anhydrase inhibitor
CA2456939A1 (en) *	2001-08-10	2003-02-20	Pharmacia Corporation	Carbonic anhydrase inhibitors
KR20040047869A (ko)	2001-09-26	2004-06-05	파마시아 이탈리아 에스.피.에이.	키나제 억제제로서 활성인 아미노인다졸 유도체, 이의제조방법 및 이를 함유하는 약제학적 조성물
CA2476665A1 (en) *	2002-02-19	2003-08-28	Pharmacia Corporation	Tricyclic pyrazole derivatives for the treatment of inflammation
ES2436524T3 (es) *	2003-05-22	2014-01-02	Nerviano Medical Sciences S.R.L.	Derivados de pirazolo-quinazolina, procedimiento para su preparación y su uso como inhibidores de cinasas
PL2125822T3 (pl) *	2006-12-21	2015-04-30	Nerviano Medical Sciences Srl	Podstawione pochodne pirazolochinazoliny, sposób ich wytwarzania oraz ich zastosowanie jako inhibitory kinaz

2004
- 2004-04-27 ES ES04741483.4T patent/ES2436524T3/es not_active Expired - Lifetime
- 2004-04-27 KR KR1020057022355A patent/KR101084871B1/ko not_active Expired - Lifetime
- 2004-04-27 OA OA1200500329A patent/OA13170A/fr unknown
- 2004-04-27 SI SI200432118T patent/SI1636236T1/sl unknown
- 2004-04-27 JP JP2006530168A patent/JP5043432B2/ja not_active Expired - Lifetime
- 2004-04-27 UA UAA200512347A patent/UA80763C2/uk unknown
- 2004-04-27 DK DK04741483.4T patent/DK1636236T3/da active
- 2004-04-27 AU AU2004240772A patent/AU2004240772B2/en not_active Expired
- 2004-04-27 MX MXPA05012573A patent/MXPA05012573A/es active IP Right Grant
- 2004-04-27 RS YUP-2005/0944A patent/RS20050944A/sr unknown
- 2004-04-27 GE GEAP20049128A patent/GEP20094664B/en unknown
- 2004-04-27 EP EP04741483.4A patent/EP1636236B1/en not_active Expired - Lifetime
- 2004-04-27 BR BR122019010200A patent/BR122019010200B8/pt active IP Right Grant
- 2004-04-27 CN CN2010105863199A patent/CN102079746A/zh active Pending
- 2004-04-27 WO PCT/EP2004/050612 patent/WO2004104007A1/en not_active Ceased
- 2004-04-27 ME MEP-2008-259A patent/ME00142B/me unknown
- 2004-04-27 RS RS20050944A patent/RS52899B/sr unknown
- 2004-04-27 PT PT47414834T patent/PT1636236E/pt unknown
- 2004-04-27 US US10/557,565 patent/US7482354B2/en not_active Expired - Lifetime
- 2004-04-27 HR HRP20050967AA patent/HRP20050967B8/hr not_active IP Right Cessation
- 2004-04-27 NZ NZ543661A patent/NZ543661A/xx not_active IP Right Cessation
- 2004-04-27 CA CA2526578A patent/CA2526578C/en not_active Expired - Lifetime
- 2004-04-27 AP AP2005003452A patent/AP2064A/xx active
- 2004-04-27 PL PL04741483T patent/PL1636236T3/pl unknown
- 2004-04-27 CN CNA2004800210752A patent/CN1826343A/zh active Pending
- 2004-04-27 BR BRPI0410563A patent/BRPI0410563B8/pt not_active IP Right Cessation
- 2004-04-27 EA EA200501849A patent/EA010904B1/ru unknown
- 2004-05-04 TW TW093112449A patent/TWI349672B/zh not_active IP Right Cessation
- 2004-05-13 MY MYPI20041795A patent/MY142019A/en unknown
- 2004-05-20 AR ARP040101748A patent/AR044543A1/es active IP Right Grant
2005
- 2005-11-18 IS IS8132A patent/IS2939B/is unknown
- 2005-11-20 IL IL172046A patent/IL172046A/en active IP Right Grant
- 2005-11-21 NO NO20055496A patent/NO334992B1/no unknown
- 2005-11-21 TN TNP2005000298A patent/TNSN05298A1/fr unknown
- 2005-11-22 CR CR8102A patent/CR8102A/es unknown
- 2005-11-22 CO CO05118410A patent/CO5721006A2/es active IP Right Grant
- 2005-11-23 ZA ZA200509486A patent/ZA200509486B/xx unknown
- 2005-11-30 EC EC2005006194A patent/ECSP056194A/es unknown
2008
- 2008-10-31 US US12/262,933 patent/US8541429B2/en not_active Expired - Lifetime
2013
- 2013-08-21 US US13/972,659 patent/US8981089B2/en not_active Expired - Lifetime
- 2013-12-09 CY CY20131101108T patent/CY1114708T1/el unknown
2015
- 2015-02-18 US US14/625,093 patent/US9464090B2/en not_active Expired - Lifetime
- 2015-11-20 AR ARP150103780A patent/AR102722A2/es unknown
2016
- 2016-09-06 US US15/256,916 patent/US9637497B2/en not_active Expired - Fee Related
2017
- 2017-03-23 US US15/467,323 patent/US10280176B2/en not_active Expired - Lifetime
2019
- 2019-03-04 US US16/291,323 patent/US20190194214A1/en not_active Abandoned
2020
- 2020-10-30 US US17/084,862 patent/US20210300935A1/en not_active Abandoned
2023
- 2023-12-22 US US18/394,122 patent/US20250011333A1/en not_active Abandoned

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2119975A (en) *	1936-08-26	1938-06-07	Beatrice S Nazel	Fluid pressure hammer

Also Published As

Publication number	Publication date
CR8102A (es)	2006-08-09
ECSP056194A (es)	2006-04-19
RS52899B (sr)	2014-02-28
US20170050972A1 (en)	2017-02-23
CA2526578A1 (en)	2004-12-02
BR122019010200B8 (pt)	2021-07-27
TW200505924A (en)	2005-02-16
TWI349672B (en)	2011-10-01
JP2007502851A (ja)	2007-02-15
GEP20094664B (en)	2009-04-10
BRPI0410563B1 (pt)	2020-12-01
WO2004104007A1 (en)	2004-12-02
RS20050944A (sr)	2008-06-05
US20170190714A1 (en)	2017-07-06
AU2004240772B2 (en)	2011-04-28
US20250011333A1 (en)	2025-01-09
AU2004240772A1 (en)	2004-12-02
SI1636236T1 (sl)	2014-01-31
BRPI0410563A (pt)	2006-06-20
IS2939B (is)	2016-03-15
ME00142B (me)	2010-10-10
NO20055496D0 (no)	2005-11-21
AP2005003452A0 (en)	2005-12-31
IS8132A (is)	2005-11-18
ZA200509486B (en)	2008-09-25
US20150158876A1 (en)	2015-06-11
HRP20050967B1 (hr)	2014-03-28
CO5721006A2 (es)	2007-01-31
US20210300935A1 (en)	2021-09-30
JP5043432B2 (ja)	2012-10-10
EA010904B1 (ru)	2008-12-30
US20070185143A1 (en)	2007-08-09
BR122019010200B1 (pt)	2020-12-15
KR20060015294A (ko)	2006-02-16
UA80763C2 (en)	2007-10-25
NO20055496L (no)	2006-02-14
KR101084871B1 (ko)	2011-11-21
MXPA05012573A (es)	2006-02-22
AR044543A1 (es)	2005-09-21
US20190194214A1 (en)	2019-06-27
MEP25908A (bs)	2010-06-10
MY142019A (en)	2010-08-16
US20090124605A1 (en)	2009-05-14
NZ543661A (en)	2009-05-31
CN102079746A (zh)	2011-06-01
NO334992B1 (no)	2014-08-18
PL1636236T3 (pl)	2014-02-28
CA2526578C (en)	2012-01-24
DK1636236T3 (da)	2013-12-09
EP1636236B1 (en)	2013-10-09
HRP20050967B8 (hr)	2014-04-25
OA13170A (en)	2006-12-13
HRP20050967A2 (en)	2007-05-31
AR102722A2 (es)	2017-03-22
US8981089B2 (en)	2015-03-17
BRPI0410563B8 (pt)	2021-05-25
US10280176B2 (en)	2019-05-07
PT1636236E (pt)	2013-12-16
US9637497B2 (en)	2017-05-02
CY1114708T1 (el)	2016-10-05
EA200501849A1 (ru)	2006-06-30
US7482354B2 (en)	2009-01-27
US8541429B2 (en)	2013-09-24
US9464090B2 (en)	2016-10-11
EP1636236A1 (en)	2006-03-22
US20130338148A1 (en)	2013-12-19
CN1826343A (zh)	2006-08-30
TNSN05298A1 (fr)	2007-07-10
ES2436524T3 (es)	2014-01-02
IL172046A (en)	2017-03-30

Publication	Publication Date	Title
TWI349672B (en)	2011-10-01	Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors
AP2048A (en)	2009-09-24	Diazepinoindole derivatives as kinase inhibitors
IL173380A0 (en)	2006-06-11	Pyridinylamino-pyrimidine derivatives as protein kinase inhibitors
IL173200A0 (en)	2006-06-11	Piperidyl-quinazoline derivatives as tyrosine kinase inhibitors
IL165515A0 (en)	2006-01-15	Bisindolyl-maleimid derivatives as kinase inhibitors
IL172132A0 (en)	2006-04-10	Thienopyridone derivatives as kinase inhibitors
PL2125822T3 (pl)	2015-04-30	Podstawione pochodne pirazolochinazoliny, sposób ich wytwarzania oraz ich zastosowanie jako inhibitory kinaz
IL173381A0 (en)	2006-06-11	2-aminophenyl-4-phenylpyrimidines as kinase inhibitors
ZA201202026B (en)	2012-11-28	PYROLO[2,3-b] PYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS
HUP0402245A3 (en)	2010-03-29	Pyrimidinyl-aminobenzamide derivatives as glycogen synthase kinase 3betha inhibitors, their use, pharmaceutical compositions containing them and process for producing them
AU2003271566A8 (en)	2004-03-03	Pyrrolopyrazines as kinase inhibitors
EP1689393A4 (en)	2008-12-17	PREPARATION OF 1,7-DISUBSTITUTED AZABENZIMIDAZOLES AS KINASE INHIBITORS
EP1670466A4 (en)	2007-04-25	PREPARATION OF 1,6,7-TRISUBSTITUTED AZABENIC ZIMIDAZOLES AS KINASE-INHIBITORS
IL182054A0 (en)	2007-07-24	Novel bis-azaindole derivatives, preparation and pharmaceutical use thereof as kinase inhibitors
EP1590333A4 (en)	2008-04-30	GLYCOGENE SYNTHASE KINASE 3BETA INHIBITOR, COMPOSITION AND PROCESS FOR PREPARING THE SAME
IL179424A0 (en)	2007-05-15	Substituted oxazole -benzoisothiazole dioxide derivatives, process for their preparation and their use
IL179758A0 (en)	2007-05-15	Substituted tetrahydro - 2h - isoquinolin - 1 - one derivatives, method for the production thereof, and use of the same as medicaments
IL175300A0 (en)	2006-09-05	Indirubin-type compounds, compositions, and methods for their use
IL172375A0 (en)	2009-02-11	Chinazoline derivatives as aurora kinase inhibitors
PL377741A1 (pl)	2006-02-20	Pochodne diarylocykloalkilowe, sposób ich wytwarzania i ich zastosowanie jako środka leczniczego
HUP0401522A2 (en)	2006-04-28	New 4-benzylidene-piperidine derivatives, pharmaceutical compositions containing the same and process for their preparation
PL378121A1 (pl)	2006-03-06	Sposób wytwarzania pirolotriazynowych inhibitorów kinazy
IL186062A0 (en)	2008-01-20	Indanyl-piperazine derivatives, method for preparing same and pharmaceutical compositions containing same
ZA200904912B (en)	2010-09-29	Substituted pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors
IL164248A0 (en)	2005-12-18	Acyl-3-carboxyphenylurea derivatives, processes for preparing them and their use